Tetsuhiro Tanaka Selected Research

Prolyl Hydroxylases (Prolyl Hydroxylase)

1/2021	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease.
9/2020	Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.
1/2020	Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
1/2020	JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
1/2020	Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
1/2020	Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
1/2020	[Multiple consequences of HIF activation in CKD].
12/2019	Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia.
1/2019	Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
1/2019	Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tetsuhiro Tanaka Research Topics

Disease

63	Hypoxia (Hypoxemia) 09/2022 - 07/2003
32	Chronic Renal Insufficiency 01/2022 - 05/2006
28	Anemia 01/2022 - 04/2007
9	Fibrosis (Cirrhosis) 01/2020 - 11/2010
8	Inflammation (Inflammations) 09/2022 - 04/2015
6	Kidney Diseases (Kidney Disease) 01/2020 - 01/2012
5	Diabetic Nephropathies (Diabetic Nephropathy) 09/2022 - 05/2006
5	Albuminuria 09/2022 - 10/2014
5	Neoplasms (Cancer) 01/2021 - 01/2011
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 09/2011
5	Proteinuria 01/2020 - 03/2008
5	Reperfusion Injury 01/2020 - 09/2004
4	Ischemia 01/2020 - 12/2005
4	Body Weight (Weight, Body) 01/2020 - 01/2017
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 06/2006
4	Renal Insufficiency (Renal Failure) 03/2015 - 08/2010
3	Nephritis 04/2015 - 04/2004
3	Hypertension (High Blood Pressure) 01/2015 - 09/2011
3	Heart Failure 01/2015 - 10/2012
2	Hyperglycemia 01/2021 - 05/2006
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2019 - 01/2019
2	Obesity 01/2019 - 01/2017
2	Chronic Kidney Failure (Chronic Renal Failure) 11/2018 - 01/2012
2	Acute Kidney Injury (Acute Renal Failure) 01/2018 - 01/2017
2	Diabetes Mellitus 05/2017 - 01/2015
2	Glomerulonephritis 04/2015 - 06/2004
2	Uremia 03/2015 - 10/2013
2	Microvascular Rarefaction 12/2014 - 04/2013
2	Edema (Dropsy) 09/2011 - 01/2011
1	Malnutrition (Nutritional Deficiencies) 01/2021
1	Muscle Weakness 01/2021
1	Diabetes Complications 01/2021
1	Sarcopenia 01/2021
1	Insulin Resistance 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Cardiomegaly (Heart Hypertrophy) 01/2020

Drug/Important Bio-Agent (IBA)

19	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2021 - 06/2006
16	Erythropoietin FDA Link 01/2021 - 04/2007
12	Prolyl-Hydroxylase InhibitorsIBA 09/2022 - 01/2009
11	Oxygen (Dioxygen)IBA 09/2020 - 06/2006
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 12/2004
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2009
8	Transcription Factors (Transcription Factor)IBA 09/2020 - 11/2005
7	enarodustatIBA 01/2020 - 01/2019
7	Pharmaceutical PreparationsIBA 01/2019 - 01/2009
6	HematinicsIBA 01/2022 - 08/2013
6	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 05/2006
5	Messenger RNA (mRNA)IBA 01/2019 - 04/2004
5	ElementsIBA 11/2011 - 12/2004
4	IronIBA 01/2021 - 01/2015
4	EnzymesIBA 01/2019 - 03/2008
4	CobaltIBA 01/2018 - 07/2003
4	IndicanIBA 03/2015 - 09/2010
4	LuciferasesIBA 11/2011 - 05/2006
3	Advanced Glycation End ProductsIBA 09/2022 - 03/2015
3	Blood Glucose (Blood Sugar)IBA 01/2021 - 04/2015
3	Small Interfering RNA (siRNA)IBA 01/2020 - 08/2015
3	CytokinesIBA 01/2020 - 01/2011
3	Hemoglobins (Hemoglobin)IBA 09/2019 - 01/2015
3	Darbepoetin alfa (Aranesp)FDA Link 02/2019 - 01/2015
3	CollagenIBA 01/2019 - 11/2010
3	RNA (Ribonucleic Acid)IBA 01/2018 - 04/2017
3	Histones (Histone)IBA 01/2018 - 01/2011
3	ChromatinIBA 05/2017 - 10/2009
3	cobaltous chloride (cobalt(II)chloride)IBA 04/2017 - 11/2011
3	Uremic ToxinsIBA 03/2015 - 08/2010
3	pimonidazoleIBA 08/2006 - 05/2004
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 09/2022 - 09/2011
2	CC ChemokinesIBA 09/2022 - 01/2018
2	bardoxolone methylIBA 09/2022 - 01/2021
2	NF-E2-Related Factor 2IBA 01/2021 - 01/2017
2	CreatinineIBA 01/2020 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 01/2020 - 09/2004
2	AdiponectinIBA 01/2020 - 01/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 11/2018
2	Streptozocin (Streptozotocin)FDA Link 01/2020 - 05/2006
2	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 11/2005
2	InterferonsIBA 10/2019 - 04/2004
2	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 05/2017
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 01/2018
2	Biological ProductsIBA 04/2017 - 01/2011
2	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2017 - 05/2006
2	AST 120IBA 01/2017 - 08/2010
2	Dipeptidyl-Peptidase IV InhibitorsIBA 04/2015 - 09/2011
2	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2014 - 09/2011
2	IncretinsIBA 10/2014 - 09/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2011 - 10/2005
2	AlbuminsIBA 01/2011 - 03/2008
1	Pentoxifylline (Trental)FDA LinkGeneric 09/2022
1	Mineralocorticoid Receptor AntagonistsIBA 09/2022
1	Janus Kinase 1IBA 09/2022
1	roxadustatIBA 01/2022
1	ClenbuterolIBA 01/2021
1	GSK1278863IBA 01/2021
1	HepcidinsIBA 01/2021
1	CholesterolIBA 01/2020
1	Atrial Natriuretic Factor (ANF)IBA 01/2020
1	NitrogenIBA 01/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020

Therapy/Procedure

17	Therapeutics 01/2021 - 06/2006